NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/02/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization490.99 mln
Float15.24 mln
Earnings Date08/11/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
29.20
Exceptional upside
Relative Strength
99
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-144
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Nuvectis Pharma is a New Jersey-based drug development company founded in 2020 and focused on creating targeted cancer treatments. Its lead program, NXP900, is currently in early-stage human trials and works by blocking specific proteins that drive tumor growth. The company aims to address cancers where patients currently have few effective treatment options.
